Anti-HER2 antibody variants
AssigneeGenentech, Inc.
InventorsHenry B. Lowman, Resi B. Gerstner, Paul J. Carter
Life of this patent
Estimating the term…
Abstract
The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains
Claims74
A polypeptide which comprises an antibody light chain variable domain comprising the hypervariable regions of SEQ ID NO:
- 1 wherein one or more amino acids selected from the group consisting of Q27(VL);
- D28(VL), N30(VL), T31(VL), A32(VL), Y49(VL), F53(VL), Y55(VL), R66(VL), H91(VL), Y92(VL), and T94(VL), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.
A polypeptide which comprises an antibody heavy chain variable domain comprising the hypervariable regions of SEQ ID NO:
- 2 wherein one or more amino acids selected from the group consisting of W95(VH), D98(VH), F100(VH), Y100a(VH), and Y102(VH), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.
An antibody that is capable of binding to the extracellular domain of HER2, which comprises the hypervariable regions of SEQ ID NO:
- 1 wherein one or more amino acids selected from the group consisting of Q27(VL), D28(VL), N30(VL), T31(VL), A32(VL), Y49(VL), F53(VL), Y55(VL), R66(VL), H91(VL), Y92(VL), and T94(VL), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.
An antibody that is capable of binding to the extracellular domain of HER2, which comprises an antibody heavy chain variable domain comprising the hypervariable regions of SEQ ID NO:
- 2 wherein one or more amino acids selected from the group consisting of W95(VH), D98(VH), F100(VH), Y100a(VH), and Y102(VH), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.
An antibody that is capable of binding to the extracellular domain of HER2, which comprises the hypervariable regions of SEQ ID NOs:
- 1 and 2 wherein one or more amino acids selected from the group consisting of D28(VL), N30(VL), T31(VL), A32(VL), Y49(VL), F53(VL), Y55(VL), R66(VL), H91(VL), Y92(VL), T94(VL), W95(VH), D98(VH), F100(VH);
- Y100a(VH), and Y102(VH), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.
An antibody that is capable of binding to the extracellular domain of HER2 which comprises the light chain variable domain of SEQ ID NO:
- 1 wherein one or more amino acids selected from the group consisting of Q27(VL), N30(VL), Y49(VL), F53(VL), Y55(VL), H91(VL), Y92(VL), and T94(VL), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.
A humanized anti-HER2 antibody 4D5-8, comprising one or more amino acid substitutions selected from the group consisting of N30(VL)S, Y49(VL)F, Y49(VL)W, F53(VL)W, Y55(VL)W, H91(VL)F, Y92(VL)W, T94(VL)S, F100(VL)W, D98(VH)W, Y100a(VH)F, and Y102(VH)V, numbered according to the Kabat numbering system.
A humanized anti-HER2 antibody 4D5-8 which comprises one or more amino acid substitutions selected from the group consisting of Y49(VL)D, F53(VL)W, Y55(VL)W, F100(VH)P, Y102(VH)K, and Y102(VH)L.
An antibody variant of a parent antibody which binds HER2, comprising an amino acid substitution at position 98 of a heavy chain variable domain thereof, and wherein the binding affinity of the antibody variant for HER2 is better than the binding affinity of the parent antibody for HER2.
A method for isolating high-affinity variants of a humanized anti-HER2 antibody, comprising:
- (a) producing anti-HER2 variants with substitutions at one or more amino acids selected from the group consisting Q27(VL), D28(VL), N30(VL), T31(VL), A32(VL), Y49(VL), F53(VL), Y55(VL), R66(VL), H91(VL), Y92(VL), T94(VL), W95(VH), D98(VH), F100(VH), Y100a(VH), and Y102(VH), within the hypervariable regions of SEQ ID NOs:
- 1 and 2, wherein numbering is according to the Kabat numbering system;
- (b) measuring binding affinities of the variants produced in (a) for HER2 extracellular domain;
- and
- (c) selecting for high-affinity variant.
Dependencies are inferred from the claim text.